PharmacoEconomics & Outcomes News 792, p33 - 2 Dec 2017 NICE invites Merck to submit CDF proposal for skin cancer drug NICE has asked Merck to submit a Cancer Drugs Fund (CDF) proposal for their immunotherapy drug, avelumab [Bavencio] – meaning patients with Merckel cell carcinoma will be able to access the drug while the company gathers more evidence for future resubmission to the NICE committee. NICE’s initial assessment showed that avelumab can extend patient survival compared with chemotherapy according to current clinical data; however, this evidence comes from one small trial and data is still being collected, so further evidence is needed to confirm these findings. Commenting on the announcement, Director of the Centre for Health Technology Evaluation at NICE, Professor Carole Longson, said "Merkel cell carcinoma is a rare and aggressive form of cancer. There are limited treatment options and the cancer can spread rapidly, which we know can be frightening for both patients and families . . . Avelumab is a promising treatment that has the potential to be cost effective. I hope Merck will work with us to submit a CDF proposal". NICE. Merck invited to submit a CDF proposal for Merkel cell cancer drug. Internet Document : 27 Nov 2017. Available from: URL: https://www.nice.org.uk/ news/article/merck-invited-to-submit-a-cdf-proposal-for-merkel-cell-cancer- drug 803286253 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792
PharmacoEconomics & Outcomes News – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera